Literature DB >> 22893598

A novel approach to the discovery of small-molecule ligands of CDK2.

Mathew P Martin1, Riazul Alam, Stephane Betzi, Donna J Ingles, Jin-Yi Zhu, Ernst Schönbrunn.   

Abstract

In an attempt to identify novel small-molecule ligands of cyclin-dependent kinase 2 (CDK2) with potential as allosteric inhibitors, we have devised a robust and cost-effective fluorescence-based high-throughput screening assay. The assay is based on the specific interaction of CDK2 with the extrinsic fluorophore 8-anilino-1-naphthalene sulfonate (ANS), which binds to a large allosteric pocket adjacent to the ATP site. Hit compounds that displace ANS directly or indirectly from CDK2 are readily classified as ATP site binders or allosteric ligands through the use of staurosporine, which blocks the ATP site without displacing ANS. Pilot screening of 1453 compounds led to the discovery of 12 compounds with displacement activities (EC(50) values) ranging from 6 to 44 μM, all of which were classified as ATP-site-directed ligands. Four new type I inhibitor scaffolds were confirmed by X-ray crystallography. Although this small compound library contained only ATP-site-directed ligands, the application of this assay to large compound libraries has the potential to reveal previously unrecognized chemical scaffolds suitable for structure-based design of CDK2 inhibitors with new mechanisms of action.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22893598      PMCID: PMC3483082          DOI: 10.1002/cbic.201200316

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  34 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  Chemical inhibitors of cyclin-dependent kinases.

Authors:  L Meijer
Journal:  Trends Cell Biol       Date:  1996-10       Impact factor: 20.808

3.  Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1.

Authors:  Chenzhong Liao; Jung-Eun Park; Jeong Kyu Bang; Marc C Nicklaus; Kyung S Lee
Journal:  ACS Med Chem Lett       Date:  2010       Impact factor: 4.345

4.  A novel mechanism by which small molecule inhibitors induce the DFG flip in Aurora A.

Authors:  Mathew P Martin; Jin-Yi Zhu; Harshani R Lawrence; Roberta Pireddu; Yunting Luo; Riazul Alam; Sevil Ozcan; Said M Sebti; Nicholas J Lawrence; Ernst Schönbrunn
Journal:  ACS Chem Biol       Date:  2012-01-27       Impact factor: 5.100

Review 5.  The retinoblastoma protein and cell cycle control.

Authors:  R A Weinberg
Journal:  Cell       Date:  1995-05-05       Impact factor: 41.582

Review 6.  Cyclin D-dependent kinases, INK4 inhibitors and cancer.

Authors:  Sagrario Ortega; Marcos Malumbres; Mariano Barbacid
Journal:  Biochim Biophys Acta       Date:  2002-03-14

Review 7.  Protein kinase inhibitors: contributions from structure to clinical compounds.

Authors:  Louise N Johnson
Journal:  Q Rev Biophys       Date:  2009-03-19       Impact factor: 5.318

Review 8.  Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.

Authors:  Georgios S Papaetis; Kostas N Syrigos
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

9.  Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.

Authors:  Yvette Mettey; Marie Gompel; Virginie Thomas; Matthieu Garnier; Maryse Leost; Irène Ceballos-Picot; Martin Noble; Jane Endicott; Jean-michel Vierfond; Laurent Meijer
Journal:  J Med Chem       Date:  2003-01-16       Impact factor: 7.446

10.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

Authors:  Jeffrey F Ohren; Huifen Chen; Alexander Pavlovsky; Christopher Whitehead; Erli Zhang; Peter Kuffa; Chunhong Yan; Patrick McConnell; Cindy Spessard; Craig Banotai; W Thomas Mueller; Amy Delaney; Charles Omer; Judith Sebolt-Leopold; David T Dudley; Iris K Leung; Cathlin Flamme; Joseph Warmus; Michael Kaufman; Stephen Barrett; Haile Tecle; Charles A Hasemann
Journal:  Nat Struct Mol Biol       Date:  2004-11-14       Impact factor: 15.369

View more
  17 in total

1.  Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.

Authors:  Wolf Wrasidlo; Leslie A Crews; Igor F Tsigelny; Emily Stocking; Valentina L Kouznetsova; Diana Price; Amy Paulino; Tania Gonzales; Cassia R Overk; Christina Patrick; Edward Rockenstein; Eliezer Masliah
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

2.  Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon.

Authors:  Afua A Akuffo; Aileen Y Alontaga; Rainer Metcalf; Matthew S Beatty; Andreas Becker; Jessica M McDaniel; Rebecca S Hesterberg; William E Goodheart; Steven Gunawan; Muhammad Ayaz; Yan Yang; Md Rezaul Karim; Morgan E Orobello; Kenyon Daniel; Wayne Guida; Jeffrey A Yoder; Anjali M Rajadhyaksha; Ernst Schönbrunn; Harshani R Lawrence; Nicholas J Lawrence; Pearlie K Epling-Burnette
Journal:  J Biol Chem       Date:  2018-02-15       Impact factor: 5.157

3.  Cyclin A2 and CDK2 as Novel Targets of Aspirin and Salicylic Acid: A Potential Role in Cancer Prevention.

Authors:  Rakesh Dachineni; Guoqiang Ai; D Ramesh Kumar; Satya S Sadhu; Hemachand Tummala; G Jayarama Bhat
Journal:  Mol Cancer Res       Date:  2015-12-18       Impact factor: 5.852

4.  Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.

Authors:  Mary E Law; Patrick E Corsino; Satya Narayan; Brian K Law
Journal:  Mol Pharmacol       Date:  2015-05-27       Impact factor: 4.436

5.  A simple model-free method for direct assessment of fluorescent ligand binding by linear spectral summation.

Authors:  Oktay K Gasymov; Adil R Abduragimov; Ben J Glasgow
Journal:  J Fluoresc       Date:  2013-09-18       Impact factor: 2.217

6.  PAK4 crystal structures suggest unusual kinase conformational movements.

Authors:  Eric Y Zhang; Byung Hak Ha; Titus J Boggon
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2017-10-07       Impact factor: 3.036

7.  Structure-based discovery of the first allosteric inhibitors of cyclin-dependent kinase 2.

Authors:  Giulio Rastelli; Andrew Anighoro; Martina Chripkova; Laura Carrassa; Massimo Broggini
Journal:  Cell Cycle       Date:  2014-06-09       Impact factor: 4.534

8.  Modulation of the voltage-gated potassium channel (Kv4.3) and the auxiliary protein (KChIP3) interactions by the current activator NS5806.

Authors:  Walter G Gonzalez; Khoa Pham; Jaroslava Miksovska
Journal:  J Biol Chem       Date:  2014-09-16       Impact factor: 5.157

9.  Tetrahydroindazole inhibitors of CDK2/cyclin complexes.

Authors:  Jae Chul Lee; Kwon Ho Hong; Andreas Becker; Joseph S Tash; Ernst Schönbrunn; Gunda I Georg
Journal:  Eur J Med Chem       Date:  2021-01-31       Impact factor: 6.514

10.  Activation pathway of Src kinase reveals intermediate states as targets for drug design.

Authors:  Diwakar Shukla; Yilin Meng; Benoît Roux; Vijay S Pande
Journal:  Nat Commun       Date:  2014-03-03       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.